Achillion's Danicopan (ACH-4471) Receives FDA's Breakthrough Therapy Designation for Paroxysmal Nocturnal Hemoglobinuria
Shots:
- The FDA’s BT designation is based on safety & efficacy data of ongoing P-II study assessing Danicopan in combination with C5 mAb for patients with paroxysmal nocturnal hemoglobinuria (PNH) who are suboptimal responders to C5 inhibitor monothx. with its expected results in Q4’19
- The US FDA’s BT designation expedite the development and review of drugs for serious or life-threatening conditions
- The Danicopan is an orally active Factor D inhibitor- act by limiting both intravascular and extravascular hemolysis and has received FDA’s ODD in 2017 with its expected onset of P-III study in H1’2020
Click here to read full press release/ article | Ref: Achillion | Image: Achillion
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com